Jim Simons Genocea Biosciences, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.01 - $1.38 $427 - $58,925	-42,700 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.96 - $1.35 $14,592 - $20,520	15,200 Added 55.27%	42,700 $53,000
Q4 2021 Feb 11, 2022	BUY	$0.95 - $1.99 $26,125 - $54,725	27,500 New	27,500 $32,000
Q2 2021 Aug 13, 2021	SELL	$2.06 - $2.82 $52,857 - $72,358	-25,659 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$2.35 - $4.01 $869,744 - $1.48 Million	-370,104 Reduced 93.52%	25,659 $70,000
Q4 2020 Feb 10, 2021	BUY	$1.91 - $2.67 $353,481 - $494,134	185,069 Added 87.84%	395,763 $958,000
Q3 2020 Nov 13, 2020	BUY	$1.81 - $5.53 $172,534 - $527,136	95,323 Added 82.62%	210,694 $482,000
Q2 2020 Aug 13, 2020	SELL	$1.66 - $3.06 $62,955 - $116,050	-37,925 Reduced 24.74%	115,371 $265,000
Q1 2020 May 14, 2020	SELL	$1.26 - $2.73 $159,030 - $344,566	-126,215 Reduced 45.16%	153,296 $264,000
Q4 2019 Feb 13, 2020	BUY	$2.05 - $2.82 $156,105 - $214,740	76,149 Added 37.45%	279,511 $579,000
Q3 2019 Nov 13, 2019	BUY	$2.9 - $4.07 $107,227 - $150,488	36,975 Added 22.22%	203,362 $590,000
Q2 2019 Aug 12, 2019	BUY	$3.47 - $6.71 $577,362 - $1.12 Million	166,387 New	166,387 $652,000

10K

Ticker GNCA
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,783,500
Description
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products incl...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.